bims-mistre Biomed News
on Mito stress
Issue of 2026–11–01
23 papers selected by
Ellen Siobhan Mitchell, MitoQ



  1. Science. 2026 Oct 29. 394(6823): 488-489
      A small molecule improves the fitness of cells containing diseased mitochondria.
    DOI:  https://doi.org/10.1126/science.aem1560
  2. Neuron. 2026 Oct 30. pii: S0896-6273(26)00725-7. [Epub ahead of print]
      A growing body of evidence implicates the menopausal transition as a neurobiological inflection point in women's brain aging and Alzheimer's disease (AD) vulnerability. Menopause is a midlife neuroendocrine transition characterized by a decline in sex steroid hormones and widespread systemic effects. The brain is not a passive recipient of ovarian hormones but an active endocrine-sensing organ. Menopause, however, does not act in isolation: the ovarian-brain axis is established embryonically, activated at puberty, remodeled during pregnancy and postpartum, and reconfigured during the menopausal transition, with implications for later-life brain aging. This review places menopause within a lifespan neuroendocrine framework, examining mechanisms by which the transition may influence the brain, including altered hormone signaling, bioenergetics, synaptic plasticity, neurovascular function, inflammation, and AD-related pathology. It then reviews evidence linking menopausal timing to neurobiological and AD vulnerability, discusses estrogen therapy, and considers menopause as a biologically plausible window for risk stratification and prevention.
    Keywords:  Alzheimer's disease; Alzheimer’s; brain aging; dementia; estrogen; hormone therapy; menopause; neuroendocrinology; neuroprotection; perimenopause; prevention; risk reduction; sex differences
    DOI:  https://doi.org/10.1016/j.neuron.2026.09.015
  3. Mol Biomed. 2026 Oct 30. pii: 233. [Epub ahead of print]7(1):
      Metabolic diseases and age-related disorders represent a major global health burden driven by the increasing prevalence of obesity and obesity-associated complications. These disorders are characterized by chronic disturbances in energy homeostasis. A key feature linking metabolic disease and aging is the activation of stress-related pathways, which contribute to progressive metabolic dysfunction. Among the endocrine mediators of cellular stress, fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) have emerged as key regulators of metabolic homeostasis. Both are induced by similar stress conditions, including nutrient imbalance, inflammation, oxidative and endoplasmic reticulum (ER) stress and mitochondrial dysfunction, and are elevated in pathophysiological conditions such as obesity, type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD) and aging. FGF21 and GDF15 also share overlapping regulatory pathways and complementary functions, suggesting a potential coordinated regulation and functional interplay. However, the extent and physiological relevance of this possible interrelationship remain incompletely understood. This review summarizes current knowledge on the regulation, tissue sources, and signaling mechanisms of FGF21 and GDF15 across metabolic diseases and aging, with particular attention to their roles as mediators of adaptive metabolic responses and their overlapping biological actions. We further discuss their context-dependent effects under acute and chronic stress and their relevance as biomarkers of metabolic dysfunction and disease progression. Collectively, this work highlights FGF21 and GDF15 as integrated stress signals linking cellular stress to systemic metabolic adaptation, providing a conceptual framework for understanding their cooperative roles and regulation in metabolic and age-related diseases, which may have therapeutic potential.
    Keywords:  Aging; FGF21; GDF15; MASLD; Obesity; Type 2 diabetes
    DOI:  https://doi.org/10.1186/s43556-026-00627-w
  4. Antioxidants (Basel). 2026 Sep 22. pii: 1219. [Epub ahead of print]15(10):
      Age-related declines in physical capacity may partly reflect impaired mitochondrial bioenergetics and oxidative stress. This systematic review and meta-analysis evaluated the effects of oral coenzyme Q10 (CoQ10) supplementation on muscle health and physical capacity in adult populations with a study-level mean or median age ≥ 40 years. MEDLINE, Embase, Web of Science, Scopus, and CENTRAL were searched through July 2026 for randomized controlled trials lasting ≥2 weeks. Directly usable evidence formed primary random-effects models, whereas assumption-dependent estimates were included only in sensitivity analyses. Effect measures were expressed as mean differences (MDs) or Hedges' g, as appropriate. Thirty-three trials involving 3317 randomized participants were included, and 21 contributed to meta-analysis. The relative VO2peak/VO2max estimate was small and imprecise (5 studies, n = 172; MD 0.73 mL·kg-1·min-1, 95% CI -0.07 to 1.54; I2 = 0%; low certainty) and remained compatible with no benefit. Primary estimates were also uncertain for 6-min walking distances, handgrip strength, lower-limb strength, chair-rise performance, exercise duration, and muscle/lean-tissue quantity. Sensitivity analyses did not materially alter the overall interpretation. Evidence certainty was low or very low for all key outcomes. Current evidence does not establish clinically meaningful benefits of CoQ10 supplementation for aerobic capacity, muscle health, or physical function.
    Keywords:  aerobic capacity; ageing; coenzyme Q10; meta-analysis; muscle strength; physical function; randomized controlled trial; systematic review
    DOI:  https://doi.org/10.3390/antiox15101219
  5. Biol Sex Differ. 2026 Jul 31. pii: 172. [Epub ahead of print]17(1):
       BACKGROUND: Epigenetic age acceleration (EAA) is a critical biomarker of aging. Hormone replacement therapy (HRT) is commonly used to alleviate age-related diseases, while glycemic status also influences the aging process. We aimed to investigate the association between estrogen and EAA, and the effects of HRT, EAA, and glycemic status on mortality.
    METHODS: Mendelian randomization (MR) established causal relationships between genetically predicted estrogen receptor expression and EAA markers (HorvathAA, HannumAA, PhenoAA, and GrimAA). Using data from the National Health and Nutrition Examination Survey, we employed Cox proportional hazards models to analyze the association between HRT and mortality, exploring whether it was modified by EAA and glycemic status.
    RESULTS: Elevated estrogen receptor α (ESR1) expression significantly decelerated PhenoAA (β -1.26; 95% CI: -2.16, -0.37; P = 0.005). HRT significantly correlated with a reduced risk of all-cause (HR: 0.65, 95% CI: 0.47-0.88; P = 0.006) and cardiovascular (HR: 0.52, 95% CI: 0.28-0.95; P = 0.033) mortality. Additionally, there was a significant three-way interaction among HRT, two types of EAA (HorvathAA and PhenoAA), and abnormal glucose status. Stratified analyses showed no significant interaction in the normal glucose subgroup; however, a significant antagonistic interaction emerged between HRT and both HorvathAA and PhenoAA in the abnormal glucose subgroup. Consequently, although HRT exhibited a protective main effect in patients with abnormal glucose, its survival benefits were significantly attenuated as their epigenetic aging accelerated.
    CONCLUSIONS: Estrogen may decelerate PhenoAA via the ESR1 pathway. In postmenopausal women, HRT is significantly associated with a reduced risk of mortality; however, this survival benefit is substantially modified by glycemic status. Future studies should evaluate whether incorporating EAA and glycemic status into HRT decision-making could optimize clinical outcomes.
    Keywords:  Epigenetic age acceleration; Estrogen receptor; Glycemic status; Hormone replacement therapy; Mortality risk
    DOI:  https://doi.org/10.1186/s13293-026-00959-w
  6. Front Aging. 2026 ;7 1920914
      Mitochondrial function is essential for brain health. Its age-related decline impairs neuronal resilience and increases risk for the development of neurodegenerative diseases. As sex is an important biological variable in both physiological and pathological brain function, in this mini review, we highlight emerging evidence of sex differences in mitochondrial content and function in the brain and what is currently understood about how they change with age. Furthermore, as physical exercise is considered a key mitigating factor in brain injury and the development of neurodegenerative diseases, we review studies that address the effects of exercise on mitochondrial function in the brain, with particular attention to those that include data from both sexes. The current understanding of the effects of sex differences and exercise on brain mitochondrial function over the lifespan is limited, but nonetheless some interesting insights are emerging. We discuss the key knowledge gaps and offer some suggestions for further research. These include defining the extent and specificity of mitochondrial alterations with age in different species, brain regions and cell types, and their modification by exercise, which is both important for advancing aging biology and for designing intervention strategies to promote healthy aging, to mitigate age-dependent cognitive decline and treat neurodegenerative diseases.
    Keywords:  age; brain; exercise; mitochondria; sex
    DOI:  https://doi.org/10.3389/fragi.2026.1920914
  7. Nutrients. 2026 Oct 21. pii: 3451. [Epub ahead of print]18(20):
      Loss of ovarian hormones leads to obesity and insulin resistance (IR), increasing the risk of cardiovascular and metabolic diseases. We previously showed that aged female ERa knockout (αKO) and ERb knockout (βKO) mice differentially respond to ovariectomy, with a greater adverse metabolic response in βKO mice. We later showed that young ovariectomized (OVX) βKO mice were somewhat resistant to exercise-mediated metabolic benefits including adipose tissue browning.
    BACKGROUND/OBJECTIVES: We tested the hypothesis that feeding a high phytoestrogen soy-based diet (SOY) would improve metabolic health in older OVX female mice and that αKO and βKO mice would differentially respond to the diet. Since phytoestrogens weakly bind ERs, and it is known that activation of ERa mediates insulin sensitizing and weight loss benefits, and ERb is known to improve adipocyte mitochondrial responses, we hypothesized that αKO mice would be less responsive to the systemic metabolic benefits of SOY, whereas βKO mice would be less responsive to adipocyte-specific benefits.
    METHODS: We examined OVX and ovary-intact aged (~1 yr) wildtype (WT), αKO, and βKO female mice (n = 7-12/group). One week following OVX, mice were randomized to receive either SOY (585 mg phytoestrogens/kg) or a phytoestrogen-free diet (<15 mg/kg, CON) and were followed for 11 weeks. Mice were assessed for body composition (EchoMRI), energy expenditure (EE via Promethion metabolic cage system), glucose tolerance (i.p. glucose tolerance test), insulin sensitivity (HOMA-IR, Adipo-IR), adipose tissue gene and protein expression for insulin signaling markers, and fasting blood lipids. To provide additional mechanistic insight, primary adipocytes were treated with phytoestrogens and assessed for insulin-mediated phosphorylation of Akt.
    RESULTS: Era mediated important metabolic benefits of SOY in aged OVX mice. OVX αKO mice were unresponsive to SOY-mediated improvements in body composition and glucose tolerance, whereas SOY improved those metrics, as well as increased spontaneous physical activity in OVX WT and βKO mice (all p < 0.05). Primary adipocyte cell culture experiments revealed that insulin-mediated phosphorylation of Akt occurred even with ERα-antagonization, with no effects of estrogen or phytoestrogen treatment, at least in the small set of experiments performed.
    CONCLUSIONS: SOY improved body composition and glucose tolerance in old OVX mice, effects that were absent in ERα-null mice. Soy-based diets may improve metabolic health in settings of ovarian hormone suppression via mechanisms requiring estrogen signaling pathway activation.
    Keywords:  adipose tissue; aging; energy expenditure; estrogen receptor; inflammation; menopause; metabolism; ovariectomy; phytoestrogens; soy
    DOI:  https://doi.org/10.3390/nu18203451
  8. Front Aging. 2026 ;7 1912337
      Retinal neurodegeneration is a major cause of irreversible vision loss and a shared feature of age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma (GL). Increasing evidence suggests that these conditions share important pathways with retinal aging, including mitochondrial dysfunction, metabolic insufficiency, redox imbalance, chronic low-grade inflammation, and progressive neuronal vulnerability. While antioxidant and micronutrient supplementation, most notably the Age-Related Eye Disease Study (AREDS) formulations, has demonstrated benefit in selected AMD populations, emerging metabolic and nutraceutical strategies targeting aging-related pathways are of unproven benefit. In this review, following a brief overview of the current landscape of investigated supplements, we synthesize preclinical and clinical evidence for a group of metabolic supplements, including nicotinamide adenine dinucleotide (NAD+) boosters, citicoline, pyruvate, and omega-3 fatty acids, that directly modulate mitochondrial bioenergetics, cellular redox state, membrane integrity, and neuroinflammatory signaling-pathways that are recognized hallmarks of biological aging and are particularly relevant to aging-related processes implicated in retinal neurodegeneration. Using a structured literature and clinical trial search, we summarize mechanistic insights and translational findings across AMD, DR, and glaucoma, emphasizing convergence on core pathways linking retinal neurodegeneration and ocular aging. Overall, current evidence supports biological plausibility and early functional or biomarker signals for these agents, particularly in glaucoma and diabetic retinal disease, although long-term efficacy remains unproven. Framing retinal disease at the intersection of neurodegeneration and aging biology, this review highlights metabolic supplementation as a promising but evolving strategy for preserving retinal function.
    Keywords:  age-related macular degeneration; diabetic retinopathy; glaucoma; mitochondrial dysfunction; neuroprotection; nicotinamide adenine dinucleotide (NAD+); retinal aging
    DOI:  https://doi.org/10.3389/fragi.2026.1912337
  9. Int J Mol Sci. 2026 Oct 14. pii: 9101. [Epub ahead of print]27(20):
      Mitochondrial dysfunction and impaired methylation are implicated in autism spectrum disorder (ASD). Leucovorin, a reduced folate that bypasses both dihydrofolate reductase and folate receptor alpha, has shown clinical benefit in small trials in children with ASD, but the underlying biology is incompletely understood. In this pre-specified biomarker substudy of a completed double-blind placebo-controlled trial (NCT02000284; NCT01602016), children with ASD received leucovorin (2 mg/kg/day, maximum 50 mg/day) or a matched placebo for 12 weeks. Peripheral blood mononuclear cell respiration was measured by extracellular flux with a graded 2,3-dimethoxy-1,4-naphthoquinone (DMNQ) challenge (38 participants; 17 leucovorin, 21 placebo) and plasma thiol-methylation metabolites were measured pre- and post-treatment (42 participants; 18 leucovorin, 24 placebo). Leucovorin increased basal, ATP-linked, proton-leak, maximal, and reserve respiration relative to the placebo (Group × Visit p ≤ 0.012, all q ≤ 0.012; Cohen's d 0.48-0.92); there was no evidence that the treatment effect varied across the tested DMNQ concentrations. In exploratory moderator analyses, folate receptor alpha autoantibody (FRAA) status modified the effect on maximal respiratory capacity and reserve capacity (both p < 0.001), with the largest gains in FRAA-positive children receiving leucovorin, and a history of neurodevelopmental regression modified the effect on basal, proton-leak and reserve respiration. The plasma SAM/SAH ratio increased (d = 0.77) and S-adenosylhomocysteine decreased (d = -0.67) on leucovorin; both were nominally significant (p = 0.020 and 0.050) but neither survived false-discovery-rate correction within the thiol family. The findings support the folate-mitochondrial-redox axis as a candidate therapeutic target in ASD and warrant replication in larger independent cohorts.
    Keywords:  S-adenosylmethionine; autism spectrum disorder; biomarker substudy; folinic acid; leucovorin; methylation; mitochondrial respiration; neurodevelopmental regression; one-carbon metabolism; peripheral blood mononuclear cells
    DOI:  https://doi.org/10.3390/ijms27209101
  10. J Bioenerg Biomembr. 2026 Oct 24. pii: 60. [Epub ahead of print]58(1):
      The development of heart failure due to hypertension is known to be accompanied by various mitochondrial dysfunctions. It has previously been established that the pyrimidine nucleoside uridine (U) exerts a protective effect on the structural and functional parameters of mitochondria under various pathological conditions. This study aimed to evaluate the functional state of mitochondria in spontaneously hypertensive rats (SHR) in the stage of the early hypertension and to investigate the effect of uridine on mitochondrial dysfunction associated with this pathology. A 30-mg/kg uridine was found not to affect blood pressure (BP) dynamics in SHR and WKY (Wistar Kyoto) animals. In SHR, the levels of thiobarbituric acid-reactive substances (TBARS) in serum increased compared to WKY. SHR cardiac mitochondria showed decrease in respiratory control ratio compared to WKY mitochondria. Injection of uridine was accompanied by a respiratory rate decrease in the SHR + U group relative to the control. Uridine increased the levels of respiratory complexes IV and V subunits in SHR. The rate of H2O2 generation in SHR cardiac mitochondria to be restored to the control levels after uridine administration. Superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities in SHR decreased; herewith, uridine caused no statistically significant changes in SOD, GPx, and catalase (CAT) activities. This nucleoside was found not to affect the levels of mitochondrial ATP-sensitive potassium channel (MITOK) subunits in both animal strains studied. Thus, uridine exhibited antioxidant effects, contributing to partial normalization of cardiac mitochondrial function in SHR in the early stages of hypertension. This was probably due to modulation of the activity of mitochondrial transport systems, without the risk of hypertensive effects. These data justify further research into uridine as a cardiomyocyte protector. Hypertension, mitochondrial dysfunctions, uridine, oxidative stress, MITOK, SHR rats, OXPHOS.
    DOI:  https://doi.org/10.1007/s10863-026-10142-w
  11. Gynecol Endocrinol. 2026 Dec 31. 42(1): 2752665
      Follicle-stimulating hormone (FSH) is traditionally regarded as a biochemical marker of menopause and declining ovarian function. However, emerging evidence suggests that its role may extend beyond reproductive physiology. During the menopause transition, FSH concentrations rise progressively, initially due to declining inhibin B and later to loss of ovarian estradiol and inhibin production. Evidence of FSH effects in bone, adipose tissue, the cardiovascular system and brain has raised the possibility of broader physiological actions. Higher FSH levels have been associated with bone loss and hip fracture risk, adverse cardiometabolic and vascular changes, and cognitive decline and Alzheimer's disease. Although these associations do not establish causality, they suggest that FSH may contribute to some consequences of reproductive aging rather than simply reflect ovarian failure. Experimental studies indicate that reducing FSH may benefit bone and adiposity, while preliminary clinical evidence regarding cognition remains inconclusive. Thus, FSH may represent not only a marker of menopause, but also a potential marker of risk and, ultimately, a therapeutic target.
    Keywords:  Follicle-stimulating hormone (FSH); bone health; cognition; menopause; reproductive aging
    DOI:  https://doi.org/10.1080/09513590.2026.2752665
  12. Eur J Appl Physiol. 2026 Oct 24.
       INTRODUCTION: Perimenopause (PERI) women experience cognitive dysfunction, sleep disturbances, and menopause-related symptoms, yet few accessible and time-efficient interventions have been evaluated. The purpose of the current study was to determine the impact of creatine monohydrate (CM) during six weeks of high-intensity resistance training (HIRT) on cognition, sleep, and menopause symptoms in PERI females.
    METHODS: PERI females (n = 51; Age: 46 ± 5 yrs) were randomized to CM (n = 18), placebo (PLA) (n = 20), or a non-training control (CON) group (n = 13). CM and PLA groups completed a 5-day loading phase (20 g·day⁻¹) followed by six weeks of maintenance (~ 4.5 g·day⁻¹) combined with twice-weekly progressive HIRT. Cognitive performance (Stroop, Rey 15-item memory test) and prefrontal oxygenation via functional near-infrared spectroscopy were assessed at baseline (BASE), pre- (PRE), and post-training (POST). Sleep and self-reported menopause symptoms (temperature sensitivity, fatigue, soreness, brain fog, and bloating) were monitored daily using a WHOOP wearable wristband.
    RESULTS: Stroop reaction time improved over time (congruent: p < 0.001; incongruent: p = 0.004) with no group differences. Prefrontal oxygenation during the Stroop test increased with CM at POST (+ 0.32 ± 2.01%) compared to a decrease with PLA (- 1.62 ± 2.01%; p = 0.003). Sleep consistency showed a time × treatment interaction (p < 0.001), with higher consistency in CM than PLA at week 6 (baseline-adjusted mean difference: +7.4% points, p = 0.015).
    CONCLUSIONS: In this exploratory analysis, CM combined with HIRT was associated with greater prefrontal oxygenation, higher sleep consistency, and fewer self-reported temperature sensitivity days relative to PLA in PERI females.
    Keywords:  Cerebral oxygenation; Exercise; Menopause transition; Midlife women
    DOI:  https://doi.org/10.1007/s00421-026-06481-6
  13. Nutrients. 2026 Oct 14. pii: 3366. [Epub ahead of print]18(20):
      Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to mitochondrial dysfunction, including altered oxidative phosphorylation, disrupted fatty-acid oxidation, redox imbalance, abnormal mitochondrial dynamics, and impaired quality control. Berberine (BBR), a plant-derived isoquinoline alkaloid used as a nutraceutical, has been described both as a partial inhibitor of respiratory-chain complex I and as an intervention that improves mitochondrial function. This narrative review critically synthesizes evidence from hepatoma cells, primary hepatocytes, animal models, and human studies to reconcile these divergent effects. The preclinical literature supports a proposed, context-dependent model in which BBR imposes an energetic constraint during nutrient overload while activating AMP-activated protein kinase- and sirtuin-linked pathways that remodel substrate handling, respiration, redox balance, mitochondrial architecture, and autophagy. The strongest mechanistic evidence supports complex I-associated respiratory remodeling, SIRT3-mediated deacetylation of long-chain acyl-CoA dehydrogenase, SIRT1-mediated stabilization of carnitine palmitoyltransferase 1A, and SIRT1-dependent autophagy. Evidence for consistent mitochondrial biogenesis, selective mitophagy, mitochondria-endoplasmic reticulum contact-site remodeling, mitochondrial DNA danger signaling, and ferroptosis regulation in MASLD remains limited. Human evidence is mixed: a recent placebo-controlled trial found no significant reduction in liver fat with pure BBR, and no included trial directly measured hepatic mitochondrial function or established a mitochondria-mediated clinical effect. Therefore, BBR is best viewed as a context-dependent modulator of hepatic mitochondrial metabolism rather than a uniform mitochondrial enhancer. Pure BBR should not be conflated with whole barberry fruit, uncharacterized botanical preparations, or berberine ursodeoxycholate (HTD1801). Translation requires characterized formulations, exposure-matched models, and direct mitochondria-focused endpoints.
    Keywords:  berberine; metabolic dysfunction-associated steatotic liver disease; mitochondrial function; mitochondrial quality control; nonalcoholic fatty liver disease; oxidative phosphorylation; oxidative stress; sirtuins
    DOI:  https://doi.org/10.3390/nu18203366
  14. BMC Womens Health. 2026 Jul 31. pii: 562. [Epub ahead of print]26(1):
      Alzheimer's Disease (AD) prevalence and lifetime risk are higher in women than men. This led to the hypothesis that menopause, with its associated changes in female hormone homoeostasis, may be an AD risk factor modifiable by hormone replacement therapy (HRT). However, HRT is not without its risks to women's health, and any recommendations must rest on sound evidence. Here, we critically review data concerning sex-specific epidemiological and biological parameters that may influence AD development. Recent epidemiological studies suggest that the age-adjusted incidence of AD is not higher in women than men. Whilst there is mechanistic experimental evidence that female sex hormones modulate the metabolism of β-amyloid and tau, the neuropathological hallmarks of AD, no clear conclusions can be drawn from studies conducted in humans. Exposure to HRT may modify the development of AD; however, data are weak and the influence of timing, duration, type of HRT, and ethnic, socioeconomic, educational and genomic factors such as APOE genotype, requires further clarification. Large prospective biobank studies in diverse populations, with long follow-up periods and application of biological consensus criteria for the diagnosis of AD provide opportunities to conclusively clarify the relationship between menopause, HRT therapy and risk for the development of AD. Based on current evidence, HRT cannot be recommended as a generic intervention for the reduction of AD risk in women. Any decision to take HRT must consider the individual circumstances and overall health of a woman.
    Keywords:  Alzheimer’s Disease; Hormone Replacement Therapy; Menopause; Neurodegeneration
    DOI:  https://doi.org/10.1186/s12905-026-04712-8
  15. Int Immunopharmacol. 2026 Oct 30. pii: S1567-5769(26)01469-4. [Epub ahead of print]191(Pt 1): 117621
      Preeclampsia (PE) is a severe pregnancy-specific disorder and a leading cause of maternal and perinatal morbidity and mortality. Although the traditional two-stage model links abnormal placentation to maternal endothelial dysfunction, it does not fully explain how placental stress is converted into persistent systemic inflammation. This review reframes the mitochondria-immune axis as a hierarchical and self-amplifying network in PE. In this model, placental hypoxia-reoxygenation, endoplasmic reticulum stress and anti-angiogenic stress act as initiating events that destabilize mitochondrial homeostasis in trophoblasts, endothelial cells and immune cells. Damaged mitochondria then release reactive oxygen species (ROS), mitochondrial DNA (mtDNA) and other danger signals, which activate innate immune sensors, including the NLRP3 inflammasome, cGAS-STING, TLR9 and NF-kB pathways. These pathways induce IL-1β, TNF-α, type I interferon signaling, complement activation, neutrophil extracellular traps and macrophage/T-cell imbalance, which in turn aggravate mitochondrial injury and sustain a pathogenic feedback loop. We further distinguish the likely contribution of this axis across PE subtypes, including early-onset, late-onset, maternal, canonical and immunological PE. The review critically evaluates circulating mtDNA and mitochondria-related genes as biomarkers, emphasizing the effects of sample processing, vesicle-bound mtDNA, cellular contamination, gestational timing and assay choice. Therapeutic opportunities are discussed according to translational maturity, from clinically relevant supportive approaches and PE-tested preclinical interventions to extrapolated mitochondrial and immunopharmacological strategies. Overall, the mitochondria-immune axis provides a structured framework for subtype-aware biomarker development and mechanism-guided intervention in PE, while highlighting the need for standardized longitudinal cohorts and pregnancy-specific safety validation.
    Keywords:  Immune dysregulation; Inflammation; Mitochondrial DNA; Mitochondrial dysfunction; Oxidative stress; Preeclampsia
    DOI:  https://doi.org/10.1016/j.intimp.2026.117621
  16. Res Sq. 2026 Sep 03. pii: rs.3.rs-10769557. [Epub ahead of print]
      Women typically exhibit slower age-associated cognitive decline than men. Here, we show that young ovary-derived blood factors transfer female cognitive resilience to the aged male brain. Administration of young female-derived blood plasma elicited greater cognitive and neurogenic enhancements in aged male recipient mice compared to young male-derived plasma. Heterochronic young ovary transplantation likewise boosted cognition, neurogenesis and synaptic-related transcriptional signatures in aged males. We identify secreted frizzled-related protein 4 (SFRP4) as an ovary-enriched circulating factor in young female plasma, of which systemic elevation in aged male mice ameliorates cognitive impairments. Mechanistically, we identify bone-derived pro-youthful factor osteocalcin as a downstream peripheral mediator of SFRP4-induced cognitive benefits. Together, these findings highlight an ovary-bone-brain axis through which blood factors confer female cognitive resilience in aging.
    DOI:  https://doi.org/10.21203/rs.3.rs-10769557/v1
  17. Biomedicines. 2026 Oct 03. pii: 2240. [Epub ahead of print]14(10):
      Skeletal muscle dysfunction is a frequent extrapulmonary complication of chronic obstructive pulmonary disease (COPD) that limits physical capacity and increases mortality. Systemic inflammation, oxidative stress, hypoxia, and aging are distinct in origin and signaling, yet each has been implicated in COPD muscle deterioration. Whether these four drivers converge on a common pathway remains unclear. This review proposes that mitophagy, the selective elimination of damaged mitochondria, serves as this hub. Rather than acting in isolation, the four drivers converge through two functionally distinct amplification axes. The inflammatory-oxidative axis escalates mitochondrial injury, while the hypoxic-aging axis progressively erodes lysosomal disposal capacity, lowering the threshold for quality-control failure. Once injury load outruns clearance capacity, retained damaged mitochondria release mtDNA and overproduce ROS, which amplify upstream inflammatory signals and further impair lysosomal function, a self-reinforcing disequilibrium in which each iteration amplifies the next. This architecture, which we term the mitophagy vortex, implies that the four factors do not add linearly but multiply through a common quality-control node, explaining why single-target interventions have consistently failed. The framework predicts that restoring lysosomal acidification or autophagic flux, rather than neutralizing individual cytokines or ROS, may carry greater therapeutic weight once the vortex is established. Targeting the mitophagy machinery at multiple levels, including its receptors, enzymes, and lysosomal function, represents a mechanistically coherent strategy for breaking the pathological cycle.
    Keywords:  aging; chronic obstructive pulmonary disease; hypoxia; mitophagy; oxidative stress; skeletal muscle dysfunction; systemic inflammation
    DOI:  https://doi.org/10.3390/biomedicines14102240
  18. Brain Sci. 2026 Sep 27. pii: 1033. [Epub ahead of print]16(10):
      Background: Subjective cognitive complaints (SCCs) in middle-aged and older adults are recognized as early warning signs of future cognitive decline. While biological risk factors have been studied extensively, less is known about how modifiable lifestyle factors, stress, mood and sleep relate to actual performance on cognitive tests. Objective: To examine associations between lifestyle (physical activity, alcohol consumption), psychosocial factors (perceived stress, mood, sleep) and standardized cognitive performance in adults with SCCs. Methods: We conducted a cross-sectional analysis using baseline data from 276 adults aged 50-75 years enrolled in the N-HANCE study. Participants completed the Test of Attentional Performance (TAP) and Digit Span (Forward and Backward). Lifestyle and psychosocial variables were assessed using structured questions and validated self-report scales. Associations were examined using Spearman correlations and Mann-Whitney U tests, with Benjamini-Hochberg correction applied across the full family of 132 predictor-outcome comparisons, followed by linear regression models adjusted for age, sex and educational attainment. Results: Educational attainment showed the strongest and most consistent associations, relating to better performance across attention and memory measures assessed (ρ = 0.21 to 0.44, all q < 0.01). Older age was associated with poorer memory span and less consistent alertness. A history of depression was associated with reduced alertness and this association was essentially unchanged after adjustment (β = -0.19, p < 0.001). Higher BMI was associated with poorer memory span (ρ = -0.18; adjusted β = -0.16, p = 0.005) and higher perceived stress with poorer working memory (Digit Span Backward ρ = -0.21; adjusted β = -0.11, p = 0.046; p = 0.062 under robust standard errors). Associations involving mood and sleep quality attenuated to non-significance after adjustment, while physical activity retained only a marginal association with divided attention. Nineteen of 132 associations survived correction for multiple comparisons. Conclusions: In adults with SCCs, educational attainment and age, a proxy of cognitive reserve and an index of aging respectively, rather than modifiable targets, accounted for the strongest associations with objective cognitive performance. Among potentially modifiable factors, a history of depression and higher BMI showed the most robust independent associations, while associations with mood and sleep did not persist after adjustment and physical activity retained only a marginal association. These cross-sectional findings identify candidate risk and resilience markers that require confirmation in longitudinal follow-up.
    Keywords:  aging; attention; cognitive performance; lifestyle; memory; subjective cognitive complaints
    DOI:  https://doi.org/10.3390/brainsci16101033
  19. Mar Drugs. 2026 Sep 26. pii: 335. [Epub ahead of print]24(10):
      Ultraviolet (UV) radiation is a major environmental stressor that disrupts cellular integrity by inducing oxidative stress, impairing mitochondrial function, and altering immune cell activity, ultimately compromising cellular homeostasis. In this context, carotenoids are widely recognized for their antioxidant and immunomodulatory properties, with C50 carotenoids emerging as a promising subgroup with enhanced biological activity compared with classical C40 carotenoids. Among them, bacterioruberin (BR), a red-pigmented C50 carotenoid mainly produced by haloarchaea, has attracted increasing interest due to its strong antioxidant and cytoprotective potential. Accordingly, this study investigated the mechanisms underlying the protective effects of a bacterioruberin-rich carotenoid extract (BRCE) against UV-induced damage in human peripheral blood mononuclear cells (PBMCs). PBMCs were pre-incubated with BRCE prior to UV exposure and intracellular reactive oxygen species (ROS), mitochondrial membrane potential (Δψm), caspase-3 activation, and the expression of B cell lymphoma 2 (Bcl-2) and granzyme A were evaluated using fluorescence-based assays via confocal microscopy and flow cytometry. BRCE attenuated oxidative stress, preserved mitochondrial membrane potential, reduced caspase-3 activation, and modulated Bcl-2 and granzyme A expression, with more pronounced effects observed at low concentrations. Overall, BRCE exerted a coordinated cytoprotective effect through modulation of oxidative stress, mitochondrial integrity, and apoptosis-related signaling pathways. These findings provide novel insight into the cellular effects associated with the bioactivity of bacterioruberin and support the growing interest in C50 carotenoids as promising photoprotective and immunomodulatory compounds.
    Keywords:  PBMCs; antioxidant; apoptosis; bacterioruberin; carotenoids; ultraviolet (UV)
    DOI:  https://doi.org/10.3390/md24100335
  20. Nutrients. 2026 Oct 16. pii: 3391. [Epub ahead of print]18(20):
      Background/Objectives: Although chondroitin sulfate (CS) is commonly used for knee osteoarthritis (OA), evidence regarding its effects on joint symptoms and physical function remains inconsistent. This study aimed to evaluate the effects of CS supplementation on joint symptoms and physical function in adults with mild knee OA. Methods: In this 12-week, randomized, double-blind, placebo-controlled trial, 100 adults with mild knee OA were randomly assigned to receive CS (1200 mg/day; n = 50) or placebo (n = 50). The primary outcomes were the Korean Western Ontario and McMaster Universities Osteoarthritis Index (K-WOMAC) total and subscale scores. Secondary outcomes comprised the pain visual analog scale (VAS), 20-m walking time, Korean Australian/Canadian Osteoarthritis Hand Index (K-AUSCAN), and grip and pinch strength. Results: At week 12, the reduction in the K-WOMAC total score was significantly greater with CS than with placebo (-19.26 ± 2.74 vs. -2.10 ± 1.37; p < 0.001), along with greater reductions in the pain, stiffness, and physical function subscale scores (all p < 0.001). Notable improvements were also observed in the pain VAS (-18.82 ± 3.50 vs. -3.04 ± 3.10 mm) and 20-m walking time (-1.40 ± 0.62 vs. 0.23 ± 0.32 s) (both p < 0.001). K-AUSCAN scores and grip and pinch strength also improved significantly compared to placebo. No clinically meaningful safety concerns were observed. Conclusions: These findings suggest that CS supplementation may be beneficial in improving joint symptoms and physical function in adults with mild knee OA, demonstrating consistent benefits across both self-reported outcomes and objective walking performance.
    Keywords:  chondroitin sulfate; functional food; joint health; joint pain; knee osteoarthritis; physical function
    DOI:  https://doi.org/10.3390/nu18203391
  21. Front Mol Biosci. 2026 ;13 1990670
      SIRT2, an NAD+-dependent deacetylase, is increasingly recognized as an important regulator of cellular metabolism and aging. By deacetylating diverse substrates, SIRT2 influences glucose metabolism, lipid metabolism, mitochondrial function, cytoskeletal dynamics, oxidative stress, and inflammatory responses, thereby contributing to cellular metabolic homeostasis and aging. Emerging evidence suggests that age-related alterations in NAD+ metabolism may affect SIRT2 activity and disrupt these processes, potentially promoting metabolic dysfunction, mitochondrial impairment, cellular senescence, and chronic inflammation. In addition, the effects of SIRT2 on aging appear to be highly context- and tissue-dependent, and its precise contribution to organismal longevity remains incompletely understood. In this review, we primarily focus on the role of SIRT2 in aging and longevity through the regulation of energy metabolism, with particular emphasis on the underlying molecular mechanisms and its interactions with metabolic and stress-responsive pathways. Understanding these mechanisms and regulations may provide new insights into SIRT2 biology and potential strategies for maintaining metabolic homeostasis and promoting healthy aging, even applications in clinic practice.
    Keywords:  SIRT2; aging; energy metabolism; lifespan; metabolic homeostasis
    DOI:  https://doi.org/10.3389/fmolb.2026.1990670
  22. Mol Med Rep. 2026 Dec;pii: 344. [Epub ahead of print]34(6):
      Metabolic dysfunction‑associated steatotic liver disease (MASLD) has emerged as a central driver of the global chronic liver disease burden. Its progression toward metabolic dysfunction‑associated steatohepatitis and advanced liver fibrosis is shifting from the traditional view of simple lipid accumulation to a dynamic pathogenic network centered on mitochondrial dysfunction. The present review systematically delineates the non‑linear kinetic evolution of mitochondrial alteration from early 'hormetic compensatory adaptation' to late 'bioenergetic collapse' during MASLD progression. The molecular basis of mitochondrial quality control, including fission/fusion dynamics, mitophagy, the mitochondrial unfolded protein response and inter‑organelle cross‑talk via mitochondria‑associated endoplasmic reticulum membranes are critically discussed. Focus is placed on the key homeostatic networks regulated by the sirtuin family (SIRT1‑SIRT7), dissecting their context‑dependent roles and current academic controversies. Finally, contemporary clinical and preclinical therapeutic strategies targeting mitochondrial metabolism are evaluated, providing a strict evidence‑graded translational perspective from basic research toward clinical precision medicine.
    Keywords:  metabolic dysfunction‑associated steatohepatitis; metabolic dysfunction‑associated steatotic liver disease; mitochondrial dysfunction; mitochondrial quality control; resmetirom; sirtuins
    DOI:  https://doi.org/10.3892/mmr.2026.14055
  23. bioRxiv. 2026 Oct 11. pii: 2026.10.05.756890. [Epub ahead of print]
      SARM1 is an inducible NADase that executes pathological axon degeneration, but how NAD+ destruction causes neuronal failure remains unclear. Because SARM1 is predicted to act outside the mitochondrial matrix, cytosolic NAD+ loss has been viewed as the critical lethal lesion. We show that SARM1 activation rapidly depletes cytosolic and mitochondrial NAD+ and collapses ATP in both compartments, revealing early, coupled metabolic failure. Enhancing mitochondrial NAD+ import through SLC25A51, the mitochondrial NAD+ transporter, preserves mitochondrial NAD+, maintains mitochondrial function, and delays axon degeneration and neuronal death despite ongoing SARM1 activity. Unexpectedly, SLC25A51 restores cytosolic NAD+-dependent metabolism, reversing a glycolytic block and increasing NAD+ synthesis during stress. Glycolytic inhibition attenuates protection, identifying cytosolic metabolic recovery as an important component of neuronal resilience. AAV-SLC25A51 improves function in a chronic SARM1-dependent neuropathy model. Thus, mitochondrial NAD+ import gates SARM1-driven degeneration by limiting coupled mitochondrial-cytosolic metabolic failure, presenting a downstream intervention point for axon preservation.
    DOI:  https://doi.org/10.64898/2026.10.05.756890